Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for September 26, 2025, now rescheduled to September 29, 2025. This postponement is to provide shareholders with additional time to consider special resolutions. The company has issued a supplemental proxy form and circular to guide shareholders on the new voting procedures, ensuring clarity and compliance in the decision-making process.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the biosciences industry. The company is involved in the development and commercialization of innovative therapies and products, focusing on addressing unmet medical needs.
Average Trading Volume: 13,634,161
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.61B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.